Patents by Inventor Christiane Amendt

Christiane Amendt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETARYLAMINONAPHTHYRIDINES
    Publication number: 20120316166
    Abstract: Novel hetarylaminonaphthyridine derivatives of formula (I) wherein X, R1, R2, R3, R4, W1, W2, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: January 10, 2011
    Publication date: December 13, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Alfred Jonczyk, Dieter Dorsch, Frank Zenke, Christiane Amendt
  • Hetaryl-[1,8]naphthyridine derivatives
    Publication number: 20120295902
    Abstract: Novel hetaryl-[1,8]naphthyridine derivatives of formula (I) wherein R1, R2, W1, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: December 17, 2010
    Publication date: November 22, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Alfred Jonczyk, Dieter Dorsch, Guenter Hoelzemann, Christiane Amendt, Frank Zenke
  • HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS
    Publication number: 20120225875
    Abstract: Novel hetarylaminoquinoline derivatives of formula (I) wherein X, Z, Het, R1, R2, R3 and R4 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: October 12, 2010
    Publication date: September 6, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Alfred Jonczyk, Christiane Amendt, Frank Zenke
  • Tetrahydroquinolines for use as modulators of the mitotic motor protein Eg5
    Patent number: 8207345
    Abstract: Compounds of the formula (I), in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: June 26, 2012
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Frank Zenke
  • 5-cyanothienopyridines for the treatment of tumours
    Patent number: 8202882
    Abstract: Novel 5-cyanothienopyridines of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: June 19, 2012
    Assignee: Merck Patent Gesellschaft MIT Beschränkter Haftung
    Inventors: Guenter Hoelzemann, Ulrich Graedler, Hartmut Greiner, Christiane Amendt, Djordje Musil, Per Hillertz
  • METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS
    Publication number: 20120130147
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 24, 2012
    Inventors: Dirk FINSINGER, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
  • ALKOXY-THIENOPYRIMIDINES AS TGF-BETA RECEPTOR KINASE MODULATORS
    Publication number: 20120101095
    Abstract: Novel alkoxy-thienopyrimidine derivatives of formula (I) wherein R1 and R2 have the meaning according to claim 1, are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: May 27, 2010
    Publication date: April 26, 2012
    Inventors: Guenter Hoelzemann, Dieter Dorsch, Hartmut Greiner, Christiane Amendt, Frank Zenke
  • Tetrahydroquinoline derivatives
    Patent number: 8110583
    Abstract: Compounds of the formula I, in which s, k, I, W, R1, R2, R3, and U have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: February 7, 2012
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, David Bruge, Kai Schiemann, Dirk Finsinger, Hans-Peter Buchstaller, Frank Zenke, Christiane Amendt
  • Triazole derivatives
    Patent number: 8093240
    Abstract: Novel triazole derivatives are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: November 24, 2006
    Date of Patent: January 10, 2012
    Assignee: Merck Patent GmbH
    Inventors: Bertram Cezanne, Christiane Amendt, Hartmut Greiner, Ulrich Graedler, Guenter Hoelzemann
  • Triazabenzo[E]azulene derivatives for the treatment of tumors
    Patent number: 8063040
    Abstract: Novel triazabenzo[e]azulene derivatives of the formula, (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: September 29, 2007
    Date of Patent: November 22, 2011
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Guenter Hoelzemann, Hartmut Greiner, Christiane Amendt
  • Tetrahydroquinolines
    Patent number: 7915416
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: March 29, 2011
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Dirk Finsinger, Wolfgang Staehle, Christiane Amendt, Ulrich Emde, Frank Zenke
  • Substituted tetrahydroquinolines
    Patent number: 7893082
    Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: February 22, 2011
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Nina Heiss, Frank Zenke
  • THIENOPYRIMIDINES
    Publication number: 20110028472
    Abstract: Novel thienopyrimidines of the formula (I), in which R1, R2 and X have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: March 23, 2009
    Publication date: February 3, 2011
    Applicant: MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Guenter Hoelzemann, Hartmut Greiner, Christiane Amendt, Frank Zenke
  • Phthalazinones
    Patent number: 7875614
    Abstract: Compounds of the formula I, in which R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3 and Y1 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: January 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Kai Schiemann, Ulrich Emde, Frank Zenke, Christiane Amendt
  • 5-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS
    Publication number: 20100234369
    Abstract: Novel 5-cyanothienopyridines of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: September 19, 2008
    Publication date: September 16, 2010
    Inventors: Guenter Hoelzemann, Ulrich Graedler, Hartmut Greiner, Christiane Amendt, Djordje Musil, Per Hillertz
  • Benzimidazole derivatives as raf kinase inhibitors
    Patent number: 7691886
    Abstract: The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to patients.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: April 6, 2010
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dirk Finsinger, Matthias Wiesner, Lars Thore Burgdorf, Christiane Amendt, Matthias Grell, Christian Sirrenberg, Frank Zenke
  • Benzimidazole carboxamides as raf kinase inhibitors
    Patent number: 7691870
    Abstract: The present invention relates to benzimidazole carboxamides of formula I, the use of the compounds of formula I of as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of pharmaceutical compositions and methods of treatment, comprising administering said pharmaceutical compositions to a patients.
    Type: Grant
    Filed: June 11, 2004
    Date of Patent: April 6, 2010
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Matthias Wiesner, Frank Zenke, Christiane Amendt, Matthias Grell, Christian Sirrenberg
  • TETRAHYDROQUINOLINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER
    Publication number: 20100076012
    Abstract: Compounds of the formula (I), in which E, R3, R4, R5, X, Y, W, Q1, Q2, Z, s and m have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: February 22, 2008
    Publication date: March 25, 2010
    Applicant: Merck Patent GmbH
    Inventors: Kai Schiemann, Dirk Finsinger, Christiane Amendt, Frank Zenke
  • Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors
    Publication number: 20100063028
    Abstract: Novel triazabenzo[e]azulene derivatives of the formula, (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: September 29, 2007
    Publication date: March 11, 2010
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Guenter Hoelzemann, Hartmut Greiner, Christiane Amendt
  • SUBSTITUTED TETRAHYDROQUINOLINES
    Publication number: 20100022579
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R5, X, Y, W, Q1, Q2, Z, s and m have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: February 21, 2008
    Publication date: January 28, 2010
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCRANKTER HAFTUNG
    Inventors: Kai Schiemann, Dirk Finsinger, Christiane Amendt, Frank Zenke